U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H17O2.Na
Molecular Weight 228.2626
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IBUPROFEN SODIUM ANHYDROUS

SMILES

[Na+].CC(C)CC1=CC=C(C=C1)C(C)C([O-])=O

InChI

InChIKey=PTTPUWGBPLLBKW-UHFFFAOYSA-M
InChI=1S/C13H18O2.Na/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15;/h4-7,9-10H,8H2,1-3H3,(H,14,15);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H17O2
Molecular Weight 205.2729
Charge -1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/20718179

Ibuprofen is a nonsteroidal anti-inflammatory agent (NSAIA) or nonsteroidal anti-inflammatory drug (NSAID), with analgesic and antipyretic properties. Ibuprofen has pharmacologic actions similar to those of other prototypical NSAIAs, which are thought to act through inhibition of prostaglandin synthesis. It’s used temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps and temporarily reduces fever. The exact mechanism of action of ibuprofen is unknown. Ibuprofen is a non-selective inhibitor of cyclooxygenase, an enzyme invovled in prostaglandin synthesis via the arachidonic acid pathway. Its pharmacological effects are believed to be due to inhibition cylooxygenase-2 (COX-2) which decreases the synthesis of prostaglandins involved in mediating inflammation, pain, fever and swelling. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. Inhibition of COX-1 is thought to cause some of the side effects of ibuprofen including GI ulceration. Ibuprofen is administered as a racemic mixture. The R-enantiomer undergoes extensive interconversion to the S-enantiomer in vivo. The S-enantiomer is believed to be the more pharmacologically active enantiomer.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Palliative
IBU-TAB

Approved Use

temporarily relieves minor aches and pains due to: headache; the common cold; muscular aches; backache; toothache; minor pain of arthritis; menstrual cramps; temporarily reduces fever

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
27.9 μg/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
103 μg × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.2 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IBUPROFEN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
IBUPROFEN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Other AEs: Cardiovascular collapse, Acidosis...
Other AEs:
Cardiovascular collapse (grade 5, 1 patient)
Acidosis (grade 5, 1 patient)
Hypothermia (grade 5, 1 patient)
Sources:
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Other AEs: Polyuria, Acidosis...
Other AEs:
Polyuria (1 patient)
Acidosis (1 patient)
Sources:
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Other AEs: Acute respiratory distress syndrome, Tachypnea...
Other AEs:
Acute respiratory distress syndrome (serious, 1 patient)
Tachypnea (serious, 1 patient)
Septic shock (serious, 1 patient)
Breathlessness (serious, 1 patient)
Septicemia (serious, 1 patient)
Sources:
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (2%)
Headache (1 patient)
Sources: Page: p.87
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources: Page: p.87
unhealthy, 44 years (range: 20-69 years)
n = 304
Health Status: unhealthy
Age Group: 44 years (range: 20-69 years)
Sex: M+F
Population Size: 304
Sources: Page: p.87
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (2 patients)
Sources: Page: p.87
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Co-administed with::
divalproex sodium
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Other AEs: Cardiovascular collapse...
Other AEs:
Cardiovascular collapse (grade 5, 1 patient)
Sources:
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Other AEs: Acidosis, Hypothermia...
Other AEs:
Acidosis (grade 5, 1 patient)
Hypothermia (grade 5, 1 patient)
Sources:
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Other AEs: Myocardial infarction, Stroke...
Other AEs:
Myocardial infarction (serious|grade 5)
Stroke (serious|grade 5)
Sources:
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Other AEs: Myocardial infarction, Stroke...
Other AEs:
Myocardial infarction (serious|grade 5)
Stroke (serious|grade 5)
Sources:
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Other AEs: Depression, Insomnia...
Other AEs:
Depression (below serious, 1 patient)
Insomnia (below serious, 1 patient)
Oropharyngeal pain (below serious, 1 patient)
Sinus congestion (below serious, 1 patient)
Sources:
97.5 mg 4 times / day multiple, oral
Dose: 97.5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 97.5 mg, 4 times / day
Sources:
unhealthy
n = 112
Health Status: unhealthy
Condition: Dental Pain
Population Size: 112
Sources:
Other AEs: Facial swelling...
Other AEs:
Facial swelling (below serious, 8 patients)
Sources:
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
Other AEs: Bleeding, Perforation...
Other AEs:
Bleeding (below serious, 2 patients)
Perforation (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acidosis grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Cardiovascular collapse grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Hypothermia grade 5, 1 patient
199800 mg single, oral
Overdose
Dose: 199800 mg
Route: oral
Route: single
Dose: 199800 mg
Sources:
unknown, 17 years
Health Status: unknown
Age Group: 17 years
Sex: F
Sources:
Acidosis 1 patient
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Polyuria 1 patient
90 g single, oral
Overdose
Dose: 90 g
Route: oral
Route: single
Dose: 90 g
Sources:
unknown, 19 years
Health Status: unknown
Age Group: 19 years
Sex: M
Sources:
Acute respiratory distress syndrome serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Breathlessness serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Septic shock serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Septicemia serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Tachypnea serious, 1 patient
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources:
unhealthy, 33 years
n = 40
Health Status: unhealthy
Age Group: 33 years
Sex: M+F
Population Size: 40
Sources:
Headache 1 patient
Disc. AE
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Dizziness 2%
Disc. AE
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources: Page: p.87
unhealthy, 42 years (range: 17-73 years)
n = 195
Health Status: unhealthy
Age Group: 42 years (range: 17-73 years)
Sex: M+F
Population Size: 195
Sources: Page: p.87
Headache 2 patients
Disc. AE
800 mg 4 times / day multiple, intravenous
Recommended
Dose: 800 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 800 mg, 4 times / day
Sources: Page: p.87
unhealthy, 44 years (range: 20-69 years)
n = 304
Health Status: unhealthy
Age Group: 44 years (range: 20-69 years)
Sex: M+F
Population Size: 304
Sources: Page: p.87
Cardiovascular collapse grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Co-administed with::
divalproex sodium
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Acidosis grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Hypothermia grade 5, 1 patient
240000 mg single, oral
Overdose
Dose: 240000 mg
Route: oral
Route: single
Dose: 240000 mg
Sources:
unknown, 49 years
Health Status: unknown
Age Group: 49 years
Sex: M
Sources:
Myocardial infarction serious|grade 5
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Stroke serious|grade 5
400 mg 4 times / day multiple, intravenous
Recommended
Dose: 400 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 400 mg, 4 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Pain
Age Group: adult
Sources:
Myocardial infarction serious|grade 5
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Stroke serious|grade 5
400 mg 6 times / day multiple, oral
Recommended
Dose: 400 mg, 6 times / day
Route: oral
Route: multiple
Dose: 400 mg, 6 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: pain
Age Group: adult
Sources:
Depression below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Insomnia below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Oropharyngeal pain below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Sinus congestion below serious, 1 patient
200 mg single, oral
Dose: 200 mg
Route: oral
Route: single
Dose: 200 mg
Sources:
unhealthy
n = 62
Health Status: unhealthy
Condition: Episodic Tension Type Headache
Population Size: 62
Sources:
Facial swelling below serious, 8 patients
97.5 mg 4 times / day multiple, oral
Dose: 97.5 mg, 4 times / day
Route: oral
Route: multiple
Dose: 97.5 mg, 4 times / day
Sources:
unhealthy
n = 112
Health Status: unhealthy
Condition: Dental Pain
Population Size: 112
Sources:
Perforation below serious, 1 patient
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
Bleeding below serious, 2 patients
10 mg/kg single, oral
Dose: 10 mg/kg
Route: oral
Route: single
Dose: 10 mg/kg
Sources:
unhealthy
n = 29
Health Status: unhealthy
Condition: Post-ERCP Pancreatitis
Population Size: 29
Sources:
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
minor
minor
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Letter: Aspirin sensitivity: other drugs.
1975 Feb
Acute renal papillary necrosis induced by ibuprofen.
1997 Jan
[Renal tubular acidosis with severe hypokalemic tetraparesis after ibuprofen intake].
1999 Apr 23
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.
1999 Dec 2
Recurrence of ibuprofen-induced aseptic meningitis in an otherwise healthy patient.
1999 Feb
Spinal antinociceptive effect of epidural nonsteroidal antiinflammatory drugs on nitric oxide-induced hyperalgesia in rats.
1999 Jul
Low-dose diclofenac, naproxen, and ibuprofen cohort study.
1999 Jul
Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells.
1999 May 21
Comparative ability of ibuprofen and N-(4-hydroxyphenyl)retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cyclooxygenase isoforms.
1999 Nov-Dec
Sensitivity of repeated interdigital web pinching to detect antinociceptive effects of ibuprofen.
2000 Apr
Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta.
2000 Feb 11
Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.
2000 Jan
Ibuprofen as effective as indomethacin for patent ductus arteriosus.
2000 Jul 25
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.
2000 Sep 7
Interpolymer complexation. II. Entrapment of ibuprofen by in-situ complexation between polyvinyl acetate phthalate (PVAP) and polyvinylpyrrolidone (PVP) and development of a chewable tablet formulation.
2001
A benefit/risk analysis of the prevention of brain ischaemia with anticoagulant drugs: when, how and whom to treat?
2001
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
[Misuse of drugs in recreational sports].
2001 Apr
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
2001 Apr
Obsessive-compulsive disorder: a neuronal membrane phospholipid hypothesis and concomitant therapeutic strategy.
2001 Apr
Group B Streptococci and inducible nitric oxide synthase: modulation by nuclear factor kappa B and ibuprofen.
2001 Apr
Ibuprofen-lysine for closure of patent ductus arteriosus.
2001 Apr
Nonsurgical female sterilization: comparison of intrauterine application of quinacrine alone or in combination with ibuprofen.
2001 Apr
IL-10 mediation of activation-induced TH1 cell apoptosis and lymphoid dysfunction in polymicrobial sepsis.
2001 Apr 7
Determination of nonsteroidal anti-inflammatory drugs in biological fluids by automatic on-line integration of solid-phase extraction and capillary electrophoresis.
2001 Feb
The use of anti-inflammatory drugs in cancer pain.
2001 Feb
[Topical administration is better than oral administration].
2001 Feb 1
The involvement of phospholipase A(2) in ethanol-induced gastric muscle contraction.
2001 Feb 16
The role of acetaminophen in the management of patients with osteoarthritis.
2001 Feb 19
Functional evidence for an inward rectifier potassium current in rat renal afferent arterioles.
2001 Feb 2
Activity profile of glycolamide ester prodrugs of ibuprofen.
2001 Jan
Effect of a single dose of ibuprofen lysinate before embryo transfer on pregnancy rates in cows.
2001 Jan
Ibuprofen for closure of patent ductus arteriosus.
2001 Jan
Ibuprofen as a chemesthetic stimulus: evidence of a novel mechanism of throat irritation.
2001 Jan
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.
2001 Jan 10
Penetration enhancement of ibuprofen from supersaturated solutions through human skin.
2001 Jan 5
Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay.
2001 Jan-Apr
Investigation of foreign substances in food.
2001 Jan-Feb
[Necrotizing fasciitis. Clinical criteria and risk factors].
2001 Mar
Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms.
2001 Mar
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough?
2001 Mar
Continuous low-level topical heat in the treatment of dysmenorrhea.
2001 Mar
NSAIDs bound to methacrylic carriers: microstructural characterization and in vitro release analysis.
2001 Mar 12
Expression of rat liver long-chain acyl-CoA synthetase and characterization of its role in the metabolism of R-ibuprofen and other fatty acid-like xenobiotics.
2001 Mar 15
Simultaneous quantification of neutral and acidic pharmaceuticals and pesticides at the low-ng/l level in surface and waste water.
2001 Mar 16
Use of glucosamine and chondroitin sulfate in the management of osteoarthritis.
2001 Mar-Apr
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
2001 May
Indomethacin and telomerase activity in tumor growth retardation.
2001 May
Chemical reactivity in solid-state pharmaceuticals: formulation implications.
2001 May 16
Microencapsulation of ibuprofen and Eudragit RS 100 by the emulsion solvent diffusion technique.
2001 May 7
Patents

Sample Use Guides

adults: take 1 tablet every 4 to 6 hours while symptoms persist. If pain or fever does not respond to 1 tablet, 2 tablets may be used; do not exceed 6 tablets in 24 hours. Children under 12 years: ask a doctor.
Route of Administration: Oral
Ibuprofen, in a 400-μM concentration, decreased the expression of Hsp70 by 23% in comparison with untreated cells, whereas other NSAID had no effect. Ibuprofen also decreased the expression of Hsp70 in H358, a human lung adenocarcinoma cell line, in a dose-dependent manner (from 0-400 uM).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:42:00 GMT 2023
Edited
by admin
on Fri Dec 15 16:42:00 GMT 2023
Record UNII
O0PJ4UZ01U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IBUPROFEN SODIUM ANHYDROUS
Common Name English
P-ISOBUTYLHYDRATROPIC ACID SODIUM SALT
Common Name English
BENZENEACETIC ACID, .ALPHA.-METHYL-4-(2-METHYLPROPYL)-,SODIUM SALT
Common Name English
SODIUM IBUPROFEN
Common Name English
Code System Code Type Description
EPA CompTox
DTXSID4040501
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
SMS_ID
100000085009
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
ECHA (EC/EINECS)
250-477-6
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
FDA UNII
O0PJ4UZ01U
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
PUBCHEM
5338317
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
CAS
31121-93-4
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
EVMPD
SUB21665
Created by admin on Fri Dec 15 16:42:01 GMT 2023 , Edited by admin on Fri Dec 15 16:42:01 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SOLVATE->ANHYDROUS
Related Record Type Details
ACTIVE MOIETY